Cadherins, catenins and cell cycle regulators: Impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial
- 1 November 2011
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (2) , 320-328
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Familial Cutaneous Melanoma2010
- Adhesion molecules and p16 expression in endocervical adenocarcinomaVirchows Archiv, 2009
- The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical studyInternational Journal of Gynecological Cancer, 2007
- Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomasAmerican Journal of Obstetrics and Gynecology, 2006
- The racial disparity in outcomes in endometrial cancer: Could this be explained on a molecular level?Gynecologic Oncology, 2006
- Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinomaInternational Journal of Gynecological Cancer, 2006
- Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Inactivation of the E-Cadherin-Mediated Cell Adhesion System in Human CancersThe American Journal of Pathology, 1998
- Decreased E-Cadherin Expression in Endometrial Carcinoma Is Associated with Tumor Dedifferentiation and Deep Myometrial InvasionGynecologic Oncology, 1994
- Prognostic Value of DNA Ploidy and S-Phase Fraction in Endometrial Cancer Stage I and II: A Prospective 5-Year Survival StudyGynecologic Oncology, 1994